$11.40
arrow_drop_down2.39%Key Stats | |
---|---|
Open | $12.66 |
Prev. Close | $12.44 |
EPS | -3.27 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 12.05 | 12.86 |
52 Week Range | 4.92 | 16.02 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -3.27 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Non-melanoma Skin Cancer is Predicted to Exhibit Remarkable Growth During the Study Period (2020–2034) | DelveInsight
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
Anaveon appoints Dieter Weinand as Chair of its Board of Directors
Advanced Melanoma Clinical Trial Pipeline Analysis - GlobeNewswire
Replimune (REPL) Gains on Positive Data From Melanoma Study